Hand Eczema

NEW ORLEANS — Phase 3 trial results found delgocitinib cream to significantly improve patient and clinician-reported outcomes of hand eczema, according to a presenter at the American Academy of Dermatology Annual Meeting.

The DELTA 2 pivotal phase 3 clinical trial showed positive topline results for the use of delgocitinib cream in adults with moderate to severe chronic hand eczema, LEO Pharma announced in a press release.

Delgocitinib cream met the primary endpoint in the DELTA 1 pivotal phase 3 clinical trial for the treatment of moderate to severe chronic hand eczema in adults, according to a press release from Leo Pharma.

Gusacitinib produced significant and rapid improvement of severity and pain in patients with moderate to severe chronic hand eczema, according to a study presented at AAD VMX 2021.

The FDA has granted fast track designation to delgocitinib cream for the potential treatment of moderate to severe chronic hand eczema in adults, Leo Pharma announced in a press release.

Lower levels of retinoid receptor expression correlated to hand eczema, according to a poster presented at American Academy of Dermatology virtual meeting.